Attached files

file filename
EX-99.1 - EX-99.1 - ACURA PHARMACEUTICALS, INCv219578_ex99-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
 


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934

April 25, 2011
Date of Report (Date of earliest event reported)
 


ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
 

 
State of New York
1-10113
11-0853640
(State of Other Jurisdiction
(Commission File Number)
 (I.R.S. Employer
of Incorporation)
Identification Number)
 

616 N. North Court, Suite 120
 Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
 
 

 
 
Item 8.01          Other Events

On April 25, 2011, the Registrant announced that its President and Chief Executive Officer, Andrew Reddick, has begun a leave of absence to address health issues. A press release announcing the foregoing is being furnished as Exhibit 99.1.

Item 9.01          Financial Statements and Exhibits

Exhibit Number
 
Description
     
99.1
  
Press Release dated April 25, 2011 Announcing Leave of Absence of Registrant’s Chief Executive Officer.

 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.
   
By:
/s/ Peter Clemens
 
Peter A. Clemens
 
Senior Vice President & Chief Financial Officer

Date:    April 25, 2011
 
 
 

 
 
EXHIBIT INDEX
 
Exhibit Number
 
Description
     
99.1
  
Press Release dated April 25, 2011 Announcing Leave of Absence of Registrant’s Chief Executive Officer.